ФарФаР - Фармацеутски факултет, репозиторијум
Универзитет у Београду, Фармацеутски факултет
    • English
    • Српски
    • Српски (Serbia)
  • Српски (ћирилица) 
    • Енглески
    • Српски (ћирилица)
    • Српски (латиница)
  • Пријава
Преглед рада 
  •   ФарФаР - Фармацеутски факултет, репозиторијум
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • Преглед рада
  •   ФарФаР - Фармацеутски факултет, репозиторијум
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • Преглед рада
JavaScript is disabled for your browser. Some features of this site may not work without it.

Are COX-2 inhibitors preferable to combined NSAID and PPI in countries with moderate health service expenditures?

Само за регистроване кориснике
2010
Аутори
Perić, Aneta
Toskić-Radojičić, Marija
Dobrić, Silva
Damjanov, Nemanja
Miljković, Branislava
Antunović, Mirjana
Vezmar, Sandra
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документу
Апстракт
Rationale In developed countries, cyclooxygenase 2 (COX-2) inhibitors were shown to be less costly than the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) in treatment of patients with high risk of serious gastrointestinal (GI) adverse effects. It is questionable if such results apply to developing countries where health service costs are lower and there is high discrepancy between generic and patent protected drug prices. We analysed the direct cost of treatment with generic NSAIDs in combination with PPIs versus branded COX-2 inhibitors in patients with high risk of serious GI adverse effects from the perspective of the public health service in Serbia. Methods Total cost of treatment of serious GI complications and the use of NSAID+PPI versus COX-2 inhibitors were calculated. A model for estimation of cost of treatment of NSAID+PPI versus COX-2 inhibitors which included the probability of developing serious GI adverse effects was devel...oped. Results Total cost of treatment of serious GI adverse effects resulted in an average of $814/patient. Considering the relative risk of such adverse effects for patients with four or more risk factors, the least costly treatment over 6 months was the use of celecoxib ($487). Compared with diclofenac+omeprazole, cost savings were estimated at $59 and $22 per patient with celecoxib and etoricoxib, respectively. Conclusion Cost savings may be achieved by using COX-2 inhibitors in patients at high risk of GI adverse effects even in countries with moderate health care service expenditures. Such possibility requires further investigation.

Кључне речи:
COX-2 inhibitors / gastrointestinal complications / non-steroidal anti-inflammatory drugs / pharmacoeconomics / proton pump inhibitors / treatment cost
Извор:
Journal of Evaluation in Clinical Practice, 2010, 16, 6, 1090-1095
Издавач:
  • Wiley-Blackwell, Malden
Пројекти:
  • Експериментална и клиничко-фармаколошка истраживања механизма дејства и интеракција лекова у нервном и кардиоваскуларном систему (RS-145001)

DOI: 10.1111/j.1365-2753.2009.01258.x

ISSN: 1356-1294

PubMed: 20662999

WoS: 000285763900012

Scopus: 2-s2.0-78650606999
[ Google Scholar ]
1
1
URI
http://farfar.pharmacy.bg.ac.rs/handle/123456789/1366
Колекције
  • Radovi istraživača / Researchers’ publications
Институција
Pharmacy

DSpace software copyright © 2002-2015  DuraSpace
О ФарФаР-у | Пошаљите запажања

OpenAIRERCUB
 

 

Комплетан репозиторијумИнституцијеАуториНасловиТемеОва институцијаАуториНасловиТеме

Статистика

Преглед статистика

DSpace software copyright © 2002-2015  DuraSpace
О ФарФаР-у | Пошаљите запажања

OpenAIRERCUB